Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 182 participants.

Also called NCT03532009

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 182 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03532009
Other papers using this trial's data
  • Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure ESC heart failure, 2023-04 DOI, PubMed 36564955, PMC10053160 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Bulgaria, Canada, Hungary, Poland, Romania, Russia, Slovakia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03532009. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-26 (actual); primary completion 2020-05-22 (actual). Results posted on 2021-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Acronym
PRIORITIZE HF
Condition
Heart Failure
Intervention (Drug)
Sodium Zirconium Cyclosilicate
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03532009
Content hash
fd3f6982984b973502cd87ab4ee6337c1c570d734b42c31e546b7d48106ee2f6